Nature__O of__O impact__O Cardiff__B-ORG University's__I-ORG research__O has__O led__O to__O the__O development__O of__O in-vitro__O blood__O screening__O and__O clinical__O diagnostic__O nucleic-acid__O amplification__O assays__O that__O have__O been__O adopted__O worldwide__O for__O the__O detection__O of__O infectious__O agents.__O
These__O assays__O have__O been__O brought__O to__O the__O market__O by__O GEN-PROBE__B-ORG Inc.__I-ORG (San__I-ORG Diego,__I-ORG USA)__I-ORG and__O offer__O improved__O detection__O sensitivities__O and__O importantly__O possess__O internal__O control__O for__O the__O nucleic__O acid__O amplification__O ensuring__O earlier__O disease__O detection__O and__O a__O reduced__O incidence__O of__O incorrect__O results.__O
The__O distinct__O contribution__O of__O Cardiff__B-LOC research__O to__O the__O products__O is__O evident__O in__O the__O respective__O `product__O inserts'__O [5.1]__O which__O cite__O patents__O (underlined__O in__O references__O [3.1]__O and__O [3.2]__O of__O Section__B-ORG 3__O above)__O upon__O which__O Cardiff__B-ORG University__I-ORG staff__O (Weeks__B-PER and/or__I-PER Woodhead)__I-PER are__O named__O inventors.__O
The__O Cardiff__B-LOC technology__O has__O led__O to__O year__O on__O year__O benefits__O to__O commerce__O and__O clinical__O practice.__O
Clinical__O adoption__O and__O commercial__O outcomes__O GEN-PROBE's__O key__O nucleic__O acid__O detection__O assays__O use__O the__O Dual__B-ORG Kinetic__I-ORG Assay__I-ORG (DKA)__I-ORG technology__O with__O more__O than__O 60__O million__O clinical__O tests__O performed__O worldwide__O each__O year.__O
In__O April__O 2012__O Hologic__B-ORG Inc.__I-ORG (a__O global__O healthcare__O company__O seeking__O to__O strengthen__O its__O diagnostic__O portfolio)__O acquired__O GEN-PROBE__B-ORG for__O $3.8__O billion__O [5.2]__O with__O GEN-PROBE__B-ORG realising__O a__O doubling__O in__O its__O value__O from__O 2008__O (NASDQ__B-ORG share__O price__O of__O $42)__O to__O the__O point__O of__O acquisition__O (share__O price__O $83).__O
GEN-PROBE__B-ORG as__O a__O wholly-owned__O subsidiary__O of__O Hologic__B-LOC continues__O to__O market__O and__O develop__O nucleic__O acid__O tests.__O
The__O Hologic__B-MISC 2012__O annual__O report__O [5.2]__O states__O "Diagnostics__O product__O sales__O increased__O 25%__O in__O fiscal__O 2012__O compared__O to__O fiscal__O 2011__O primarily__O due__O to__O the__O inclusion__O of__O GEN-PROBE,__B-ORG which__O contributed__O $86.7__O million__O in__O revenue".__O
Some__O of__O the__O tests__O that__O have__O seen__O first-user__O adoption__O in__O the__O assessment__O period__O are__O described__O below.__O
Blood__O screening__O assays:__O GEN-PROBE's__B-MISC blood__O screening__O assays__O are__O marketed__O by__O Novartis__B-MISC Diagnostics__I-MISC under__O the__O PROCLEIX&#174;__B-MISC trade__O mark__O [5.3.,5.4],__O with__O those__O approved__O for__O the__O Tigris&#174;__B-MISC platform__O shown__O in__O Table__B-LOC 1;__O Tigris&#174;__O is__O a__O fully__O automated__O robotic__O instrument__O enabling__O high-throughput__O sample__O processing__O and__O sample__O containment.__O
Worldwide__O more__O than__O 80__O million__O units__O of__O blood__O are__O donated__O annually__O with__O screening__O performed__O for__O infectious__O agents__O at__O major__O reference__O laboratories.__O
The__O most__O common__O screens__O are__O for__O HIV,__B-ORG hepatitis__O C__O (HCV),__B-ORG hepatitis__O B__O (HCB)__B-PER and__O West__B-LOC Nile__I-LOC Virus__I-LOC (WNV).__I-LOC
The__O PROCLEIX__B-ORG assays__O for__O these__O indications__O use__O the__O Cardiff__B-ORG DKA__I-ORG technology__O and__O importantly__O have__O been__O designed__O and__O approved__O for__O use__O on__O Tigris&#174;.__B-LOC
Since__O 2008__O the__O number__O of__O Tigris&#174;__O platforms__O in__O worldwide__O use__O at__O major__O blood__O testing__O centres__O has__O doubled__O from__O 200__O units__O (2008)__O to__O 390__O units__O in__O 2011__O [5.5];__O typically__O a__O single__O Tigris&#174;__B-ORG unit__O is__O sufficient__O for__O a__O single__O testing__O centre.__O
Table__B-PER 1:__O PROCLEIX__B-ORG Tigris&#174;__O assays__O PROCLEIX__B-ORG WNV__O PROCLEIX__O ULTRIO__O PROCLEIX__O ULTRIO__O Plus__O PROCLEIX__O ULTRIO__O Elite__O Infectious__O agent__O WNV__O HIV-1,__O HCV,__O HBV__O HIV-1,__O HCV,__O HBV__O HIV-1,__O HCV,__O HBV,__O HIV-2__O First__O approval__O date__O on__O Tigris&#174;__B-MISC platform__O CE__O marked__O and__O FDA__B-ORG approved__O in__O March__O 2007__O CE__O marked__O and__O FDA__B-ORG approved__O to__O include__O HBV__B-ORG testing__O in__O 2008__O CE__B-ORG marked__O in__O 2009__O and__O FDA__B-ORG approved__O 2012__O CE__B-ORG marked__O in__O 2012__O under__O further__O development__O for__O other__O regions__O Country__B-ORG approvals__O at__O 2013__O (new__O approvals__O since__O 21/12/2009)[5.4]__O 28__O EU__B-ORG USA__I-ORG 6__O other__O (2)__O 28__O EU__B-ORG USA__I-ORG 26__O other__O (9)__B-ORG 28__O EU__B-ORG 19__O other__O (19__O inc.__O USA)__B-ORG 28__O EU__B-ORG Notes:__O (a)__O CE__O =__O marked__O compliant__O for__O Europe__B-ORG &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;__I-ORG (b)__I-ORG PROCLEIX__I-ORG ULTRIO__I-ORG Plus__I-ORG provides__O improved__O detection__O sensitivity__O to__O the__O ULTRIO__B-MISC assay__I-MISC The__I-MISC PROCLEIX__I-MISC assays__O have__O a__O ca.__O
32%__O share__O of__O the__O global__O blood__O screening__O market__O (i.e.__O
25__O million__O assays__O per__O year)__O and__O are__O used__O in__O ca.__O
80%__O (14.5__O million__O tests)__O of__O US__B-LOC blood__O screens__O [5.3,5.4,5.6].__O
The__O PROCLEIX__B-ORG assays__O yield__O product__O sales__O to__O GEN-PROBE__B-ORG of__O ca.__O
$200__O million__O per__O year__O [5.3,5.6]__O with__O ca.__O
$16__O million__O p.a.__O
representing__O "at__O cost__O sales"__O of__O the__O Tigris&#174;__B-MISC instrumentation__O platform__O [5.6];__O in__O 2012__O the__O FDA__B-ORG approved__O GEN-PROBE's__B-MISC low-to__O mid-volume__O throughput__O testing__O platform__O (Panther&#174;)__B-ORG which__O will__O use__O the__O DKA-based__B-MISC assays.__O
The__O DKA-based__B-MISC assays__O represent__O a__O clinical__O advance__O to__O blood__O screening__O services.__O
For__O example,__O in__O 2011__O the__O South__B-ORG African__I-ORG National__I-ORG Blood__I-ORG Service__I-ORG showed__O PROCLEIX__O ULTRIO__O to__O identify__O 9744__O contaminated__O blood__O donation__O units__O from__O 3.8__O million__O tested,__O with__O 447__O of__O these__O positive__O samples__O not__O otherwise__O detected__O by__O existing__O approaches__O [5.7].__O
In__O adopting__O PROCLEIX__B-ORG ULTRIO__O the__O Australian__B-ORG National__I-ORG Blood__I-ORG Authority__I-ORG (2010)__O showed__O the__O risk__O of__O transmission__O of__O HBV__B-ORG from__O blood__O donations__O was__O decreased__O by__O 33%__O relative__O to__O HBsAg__B-ORG serology__O [5.8].__O
Clinical__O diagnostic__O assays__O for__O sexually__O transmitted__O disease__O (STD):__B-ORG GEN-PROBE's__B-MISC APTIMA__O family__O of__O clinical__O diagnostic__O STD__O assays__O all__O utilise__O Cardiff__B-ORG technology.__O
Placement__O of__O Tigris&#174;__B-MISC platforms__O worldwide__O for__O APTIMA__B-ORG STD__I-ORG diagnostics__O has__O increased__O 66%__O from__O 150__O units__O (2008)__O to__O 250__O units__O in__O 2011__O [5.5].__O
APTIMA__B-LOC Tigris&#174;__B-MISC products__O approved__O 2008__O onward__O include:__O APTIMA__B-ORG Trichomonas__I-ORG vaginalis__O (CE__O marked__O 2010__O and__O FDA__B-ORG approved__O 2011).__O
The__O only__O FDA-approved__B-MISC nucleic__O acid__O amplification__O test__O to__O specifically__O detect__O this__O parasite,__O which__O causes__O trichomoniasis,__O the__O most__O common__O curable__O STD__B-ORG (the__I-ORG Center__I-ORG for__O Disease__B-ORG Control__I-ORG estimates__O 7.4__O million__O cases__O p.a.__O
in__O USA).__B-LOC
APTIMA__O HPV__O (CE__O marked__O 2008__O and__O FDA__B-ORG approved__O 2011)__O which__O detects__O the__O presence__O of__O one__O or__O more__O of__O the__O high__O risk__O 14__O subtypes__O of__O human__O papillomavirus__O (HPV)__B-ORG associated__O with__O cervical__O cancers;__O HPV__B-ORG is__O the__O etiological__O agent__O responsible__O for__O more__O than__O 99%__O of__O all__O cervical__O cancers.__O
APTIMA__B-ORG HPV__I-ORG Genotype__I-ORG 16,__O 18/45__O (FDA__B-ORG approved__O 2012).__O
Detects__O the__O presence__O of__O the__O very__O high__O risk__O HPV__O genotypes__O 16__O and__O 18__O or__O 45__O associated__O with__O 80%__O of__O invasive__O cervical__O cancers.__O
In__O 2012__O USA__B-MISC healthcare__O professions__O and__O USA__B-LOC government__O recommended__O HPV__B-ORG screening__O every__O 5__O years__O in__O women__O over__O 30__O years.__O
In__O clinical__O studies__O involving__O approximately__O 45,000__O women__O the__O APTIMA__B-ORG HPV__B-ORG assay__O (detecting__O certain__O mRNAs)__B-ORG has__O consistently__O shown__O similar__O sensitivity__O and__O better__O specificity__O than__O the__O most__O frequently__O used__O DNA-based__B-ORG tests.__O
Based__O on__O a__O clinical__O evaluation__O of__O more__O than__O 10,000__O US__B-LOC women__O with__O normal__O cytology__O results,__O the__O APTIMA__B-ORG HPV__B-ORG assay__O had__O 24%__O fewer__O false__O positives__O than__O the__O leading__O FDA-approved__B-MISC DNA__B-ORG test__O [5.9].__O
GEN-PROBE__O APTIMA__O STD__O kits__O using__O the__O Cardiff__B-LOC technology__O hold__O a__O 49%__O global__O market__O share__O with__O ca.__O
29__O million__O tests__O p.a.__O
[5.5]__O and__O revenue__O of__O ca.__O
$200__O million__O (2008)__O rising__O to__O over__O $350__O million__O in__O 2011__O [5.3].__O
In__O 2013__O Hologic__O entered__O into__O a__O strategic__O alliance__O with__O Quest__B-MISC Diagnostics__I-MISC (the__O world's__O largest__O clinical__O diagnostics__O testing__O company)__O who__O will__O use__O APTIMA__B-MISC STD__O assays__O in__O diagnostic__O services__O [5.10].__O
The__O Cardiff__B-LOC research__O was__O transformative__O in__O providing__O a__O solution__O to__O the__O unmet__O regulatory__O need__O for__O the__O internal__O control__O of__O nucleic__O acid__O amplification__O in__O high__O sensitivity__O in-vitro__O screening__O and__O diagnostic__O assays.__O
The__O technology__O has__O been__O adopted__O by__O the__O market__O leader__O in__O nucleic__O acid__O diagnostics__O in__O a__O range__O of__O clinical__O assays__O for__O infectious__O agents.__O
The__O technology__O has__O achieved__O worldwide__O reach__O and__O underpinned__O significant__O commercial__O and__O clinical__O practice__O uptake__O [5.3].__O
